A randomized, controlled clinical trial comparing remimazolam to propofol when combined with alfentanil for sedation during ERCP procedures
Authors' conclusion
During elective ERCP, patients administered with remimazolam showed fewer respiratory depression events under deep sedation with hemodynamic advantages over propofol when administered in combination with alfentanil.
Study context
- Population
- Patients undergoing elective ERCP under deep sedation, Tianjin Nankai Hospital, Chinarandomised
- Participants
- 518 patients
- Comparison
- Remimazolam-alfentanil vs propofol-alfentanil sedation
- Remimazolamn = 250
- Propofoln = 255reference
- Primary endpoint
- Hypoxia (SpO2 < 90% for >10 s)
- Follow-up
- During ERCP
Methodological detailssingle-centre
- Single-centre
Primary result
As reported in the abstract
P = 0.04
Further findings
| Outcome | P value |
|---|---|
| Airway maneuvering due to hypoxiaSignificantly greater in the propofol group | P = 0.04 |
Patient satisfaction
- Higher satisfaction scores with remimazolam; same sedation recommended for next ERCP
Procedure and sedation time
- Procedure time much longer in the remimazolam group (attributed to disease complexity), with longer sedation time
Safety
| Outcome | P value |
|---|---|
| HypotensionLower percentage with remimazolam | P < 0.001 |
Original publication
A randomized, controlled clinical trial comparing remimazolam to propofol when combined with alfentanil for sedation during ERCP procedures. J Clin Anesth. Published 9 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →